Overview

NCI Definition [1]:
An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, PARP inhibitor AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks and promotes genomic instability and eventually leads to apoptosis. This may enhance the cytotoxicity of DNA-damaging agents. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks. The PARP-mediated repair pathway is dysregulated in a variety of cancer cell types.

Azd5305 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating azd5305, 1 is phase 1/phase 2 (1 open).

Breast carcinoma, ovarian carcinoma, and pancreatic carcinoma are the most common diseases being investigated in azd5305 clinical trials [2].

Drug Details

Synonyms [2]:
azd 5305, parp inhibitor azd5305, azd-5305
Drug Target(s) [2]:
PARP1, PARP2, PARP6
NCIT ID [1]:
C176783

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.